Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 9, 2008, Pages 1067-1077

  Sung, J J Y ^a   Tsoi, K K F ^a   Wong, V W S ^a   Li, K C T ^a   Chan, H L Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; TELBIVUDINE; VIRUS DNA;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEROCONVERSION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; NUCLEOSIDES; NUCLEOTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 53549107488     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03816.x     Document Type: Article

References (42)

1. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988 8 : 493 6.
2. Fattovich G, Brollo L, Giustina G, et al. Natural history and prognostic factors for chronic hepatitis B. Gut 1991 32 : 294 8.
3. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981 ii : 1129 32.
4. Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008 28 : 79 87.
5. McMahon BJ, Bulkow L, Harspter A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000 32 : 842 6.
6. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B a e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002 347 : 168 74.
7. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA levels and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005 97 : 265 72.
8. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
9. Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008 26 : 177 82.
10. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004 53 : 1494 8.
11. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carrier. Gastroenterology 2003 124 : 327 34.
12. Chan HLY, Tsui SKW, Tse CH, et al. Epidemiological and virological characteristics of two subgroups of genotype C hepatitis C virus. J Infect Dis 2005 191 : 2022 32.
13. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Healthcote J. Effect of alpha-interferon on treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993 119 : 312 23.
14. Shiratori Y, Yokosuka O, Imaeki F, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005 142 : 105 14.
15. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003 124 : 105 17.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 51.
17. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997 26 : 1338 42.
18. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998 83 : 901 9.
19. Brunetto MR, Oliveri F, Koehler M, Zahm F, Bonino F. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998 351 : 1535 9.
20. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998 82 : 827 35.
21. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998 5 : 389 97.
22. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999 30 : 257 64.
23. Mazzella G, Saracco G, Festi D, et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999 94 : 2246 50.
24. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001 34 : 306 13.
25. Tangkijvanich P, Thong-ngam D, Mahachai V, Kladchareon N, Suwangool P, Kullavanijaya P. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health 2001 32 : 452 8.
26. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001 34 : 139 45.
27. Truong BX, Seo Y, Kato M, et al. Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med 2005 16 : 279 84.
28. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007 46 : 45 52.
29. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl J Med 2004 351 : 1521 31.
30. Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005 32 : 173 84.
31. Patheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005 42 : 121 9.
32. Yuen MF, Seto WK, Chow DH, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007 12 : 1295 303.
33. Eun JR, Lee HJ, Lee SH, et al. The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in hepatitis B virus-related liver cirrhosis. Hepatology 2007 46 : 664A 5A.
34. Lin SM, Tai DI, Chien RN, Sheen IS, Chu CM, Liaw YF. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepat 2004 11 : 349 57.
35. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999 29 : 971 5.
36. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. J Hepatol 1994 20 : 175 80.
37. Chien RN, Sheen IS, Chu CM, Liaw YF. Beneficial effect of prednisolone priming and the need of maintenance interferon therapy in patients with chronic hepatitis B. J Hepatol 1993 18 : S24.
38. Liaw YF, Farrell G, Sung JJY, et al. Disease progression in chronic hepatitis B with advanced fibrosis or cirrhosis. J Hepatol 2005 42 : 183.
39. Liaw Y-F, Sung JJY, Chow WC, Shue K, Keene O, Farrel G. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003 38 : 262A 3A.
40. van Zonneveld M, Zondervan PE, Cakaloglu Y, et al. Peg-interferon improves liver histology in patients with HBeAg positive hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006 26 : 399 405.
41. Giannelli G, Bergamini C, Marinosci F, et al. Antifibrogenic effect of IFN-alpha2b on hepatic stellate cell activation by human hepatocytes. J Interferon Cytokine Res 2006 26 : 301 8.
42. Tasci I, Mas MR, Vural SA, et al. Rat liver fibrosis regresses better with pegylated interferon alpha-2b and ursodeoxycholic acid treatment than spontaneously recovery. Liver Int 2006 26 : 261 8.